Report Details

Global Multiple Sclerosis Drugs Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025

ID : 7745244
Date : May 2019
Pages : 204 Pages
Industry : Pharmaceutical and Healthcare


Global Multiple Sclerosis Drugs Market:
Global multiple sclerosis drugs market estimated to be valued US$ XX Mn in 2018 and poised to grow at CAGR of XX% over 2019-2025. Market for multiple sclerosis drugs projected to reach US$ XX Mn by 2025.

Multiple Sclerosis MS is a demyelinating disease that affects spinal cord and brain. Multiple sclerosis damages myelin sheath, material that surrounds and protects nerve cells. This damage blocks or slows down messages between brain and body. The exact cause of the Multiple Sclerosis disease is unknown but it is an autoimmune disease. Some of the major problems include doubled vision, psychological, mental disturbances and not having coordination in body movements. Most of the people diagnosed with MS are between the age 20 to 50 years and it can occur in young children and significantly older adults.



The unmet need of drugs for the treatment of multiple sclerosis, extensive R&D pipelines and prevalence of the disease are driving factors for the market growth of Multiple Sclerosis drug market. According to the Atlas MS, there are about 2.3 million people are with multiple sclerosis, and most of the patients are not diagnosed with multiple sclerosis and certain parts of the world due to the lacking of healthcare infrastructure and unawareness. The advancements in the biomedical science about to create a profitable opportunities for multiple sclerosis drug makers in near future. However patent expiry of the key drugs is key restraint for multiple sclerosis market, In addition strengthening of regulatory requirements and procedures also making difficulties in steady market growth.



Multiple sclerosis drug market can be segmented into mode of administration, distribution channel, and drug class



Based on route of administration, multiple sclerosis drugs market can be segmented into

Oral
Parenteral


Based on distribution channel, multiple sclerosis drugs market can be segmented into

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy


Based on drug class, multiple sclerosis drugs market can be segmented into

Disease Modifying Drugs DMDs
Steroids
Others


The global multiple sclerosis drugs market is majorly influenced by increased number of patients from secondary progressive relapsing-remitting multiple sclerosis. The awareness in identifying multiple sclerosis disease conditions increased because of organizations such as National MS society and Multiple Sclerosis Association of America MSAA are actively involved in educating the people regarding associated symptoms and increasing the awareness. The presence of strong pipeline drugs such as pleneva BTG international Ltd., cladribine Merck &Co., Inc and their expected commercialization witness to boost the market share. Companies also actively involved in collaborating with other drug manufacturers for development of drugs such as ampryra Acordda Therapeutics and Biogen Idec, laquinimod Active Biotech and Teva Pharmaceuticals, and rebif Merck Serono and Pfizer. These initiatives are enabling the manufactures to strengthen their product share in Multiple sclerosis drug market. In Multiple sclerosis drug market segments immunomodulators are predominantly used compared to other segments. On the arrival of the easier-to-use oral drugs, market share of the injectables has decreased.



Geographically multiple sclerosis drug market segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Among these regions North America is more dominating in Multiple sclerosis drug market. Multiple sclerosis related healthcare estimated more than $10bn in U.S. In North America, U.S. dominates overall market and followed by Canada. In Europe countries like Italy, Spain, and the UK holds the major share due to increased prevalence rate of multiple sclerosis. In Asian pacific region developing countries like regions like India China have advantage for the drug makers over the developed markets due to low cost of production and high availability of talent pool. Because most of the multiple sclerosis drug are biomedical drugs and requires more investment and time for developing biological products.



Key market players in multiple sclerosis drug market include Novartis AG Switzerland, Teva Pharmaceutical industries Ltd. Israel, Biogen, Inc. U.S., Merck & Co., Inc. U.S., Sanofi S.A. France, Acorda Therapeuitics U.S., Pfizer Inc. U.S., Bayer AG Germany and Medtronic plc Questcor Pharmaceuiticals U.S. to name a few.

 

In March 2018, U.S. FDA approved ocrevus Genetech USA,Inc. to treat adult patients with relapsing form of multiple sclerosis and primary progression multiple sclerosisPPMS.And this is first to treat this type of Multiple Sclerosis




In 2015, Bayer Healthcare Pharmaceuticals Inc. launched betaconnect, the first electric auto injector to treat of multiple sclerosis


Report Outline:



The report provides granular level information about the market size, regional market share and forecast from 2019-2025
The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
The report tracks recent innovations, key developments and startup’s details that are working in the industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
1. Executive summary
2. Global Multiple Sclerosis Drugs Market Introduction
2.1. Global Multiple Sclerosis Drugs Market – Taxonomy
2.2. Global Multiple Sclerosis Drugs Market –Definitions
2.2.1. Drug Class
2.2.2. Distribution Channel
3. Global Multiple Sclerosis Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Multiple Sclerosis Drugs Market Dynamics – Factors Impact Analysis
3.6. Global Multiple Sclerosis Drugs Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.7. Global Multiple Sclerosis Drugs Market – Recent Product Launches
4. Global Multiple Sclerosis Drugs Market Analysis, 2014 - 2018 and Forecast, 2019 – 2025
4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
4.2. Year-over-Year Y-o-Y Growth Analysis %
4.3. Market Oppurtunity Analysis
5. Global Multiple Sclerosis Drugs Market, By Drug Class, 2014 - 2018 and Forecast, 2019 - 2025
5.1. Disease Modifying Drugs DMDs
5.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
5.1.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
5.1.3. Market Opportunity Analysis
5.2. Steroids
5.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
5.2.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
5.2.3. Market Opportunity Analysis
5.3. Others
5.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
5.3.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
5.3.3. Market Opportunity Analysis
6. Global Multiple Sclerosis Drugs Market, By Route of Administration, 2014 - 2018 and Forecast, 2019 - 2025
6.1. Oral
6.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
6.1.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
6.1.3. Market Opportunity Analysis
6.2. Parenteral
6.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
6.2.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
6.2.3. Market Opportunity Analysis
7. Global Multiple Sclerosis Drugs Market Forecast, By Distribution Channel, 2014 - 2018 and Forecast, 2019 - 2025
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
7.1.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
7.2.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
7.3.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
7.3.3. Market Opportunity Analysis
8. Global Multiple Sclerosis Drugs Market Forecast, By Region, 2014 - 2018 and Forecast, 2019 - 2025
8.1. North America
8.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.1.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.2.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.3.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.4.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 Revenue, USD Mn
8.5.2. Year-over-Year Y-o-Y Growth Analysis % and Market Share Analysis %
8.5.3. Market Opportunity Analysis
8.6. Global Multiple Sclerosis Drugs Market - Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Region, 2019 – 2025
9. North America Multiple Sclerosis Drugs Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
9.1.1. Drug Class Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth %, and Market Share %
9.1.1.1. Disease Modifying Drugs DMDs
9.1.1.2. Steroids
9.1.1.3. Others
9.1.2. Route of Administration Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
9.1.2.1. Oral
9.1.2.2. Parenteral
9.1.3. Distribution Channel Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
9.1.3.1. Retail Pharmacies
9.1.3.2. Hospital Pharmacies
9.1.3.3. Online Pharmacies
9.1.4. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn Y-o-Y Growth % and Market Share %
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Multiple Sclerosis Drugs Market - Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2019 – 2025
9.1.6. North America Multiple Sclerosis Drugs Market Dynamics – Trends
10. Europe Multiple Sclerosis Drugs Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
10.1.1. Drug Class Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth %, and Market Share %
10.1.1.1. Disease Modifying Drugs DMDs
10.1.1.2. Steroids
10.1.1.3. Others
10.1.2. Route of Administration Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
10.1.2.1. Oral
10.1.2.2. Parenteral
10.1.3. Distribution Channel Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
10.1.3.1. Retail Pharmacies
10.1.3.2. Hospital Pharmacies
10.1.3.3. Online Pharmacies
10.1.4. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
10.1.4.1. Germany
10.1.4.2. UK
10.1.4.3. France
10.1.4.4. Spain
10.1.4.5. Italy
10.1.4.6. Russia
10.1.4.7. Poland
10.1.4.8. Rest of Europe
10.1.5. Europe Multiple Sclerosis Drugs Market - Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2019 – 2025
10.1.6. Europe Multiple Sclerosis Drugs Market Dynamics – Trends
11. Asia-Pacific Multiple Sclerosis Drugs Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
11.1.1. Drug Class Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth %, and Market Share %
11.1.1.1. Disease Modifying Drugs DMDs
11.1.1.2. Steroids
11.1.1.3. Others
11.1.2. Route of Administration Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
11.1.2.1. Oral
11.1.2.2. Parenteral
11.1.3. Distribution Channel Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
11.1.3.1. Retail Pharmacies
11.1.3.2. Hospital Pharmacies
11.1.3.3. Online Pharmacies
11.1.4. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn,
Y-o-Y Growth %, and Market Share %
11.1.4.1. Japan
11.1.4.2. China
11.1.4.3. India
11.1.4.4. ASEAN
11.1.4.5. Australia & New Zealand
11.1.4.6. Rest of Asia-Pacific
11.1.5. Asia-Pacific Multiple Sclerosis Drugs Market - Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2019 – 2025
11.1.6. Asia-Pacific Multiple Sclerosis Drugs Market Dynamics – Trends
12. Latin America Multiple Sclerosis Drugs Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
12.1.1. Drug Class Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth %, and Market Share %
12.1.1.1. Disease Modifying Drugs DMDs
12.1.1.2. Steroids
12.1.1.3. Others
12.1.2. Route of Administration Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
12.1.2.1. Oral
12.1.2.2. Parenteral
12.1.3. Distribution Channel Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
12.1.3.1. Retail Pharmacies
12.1.3.2. Hospital Pharmacies
12.1.3.3. Online Pharmacies
12.1.4. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
12.1.4.1. Brazil
12.1.4.2. Mexico
12.1.4.3. Argentina
12.1.4.4. Venezuela
12.1.4.5. Rest of Latin America
12.1.5. Latin America Multiple Sclerosis Drugs Market - Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2019 – 2025
12.1.6. Latin America Multiple Sclerosis Drugs Market Dynamics – Trends
13. Middle East & Africa Multiple Sclerosis Drugs Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
13.1.1. Drug Class Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth %, and Market Share %
13.1.1.1. Disease Modifying Drugs DMDs
13.1.1.2. Steroids
13.1.1.3. Others
13.1.2. Route of Administration Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
13.1.2.1. Oral
13.1.2.2. Parenteral
13.1.3. Distribution Channel Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth % and Market Share %
13.1.3.1. Retail Pharmacies
13.1.3.2. Hospital Pharmacies
13.1.3.3. Online Pharmacies
13.1.4. Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue USD Mn, Y-o-Y Growth %, and Market Share %
13.1.4.1. Gulf Cooperation Council GCC Countries
13.1.4.2. Israel
13.1.4.3. South Africa
13.1.4.4. Rest of MEA
13.1.5. MEA Multiple Sclerosis Drugs Market - Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2019 – 2025
13.1.6. MEA Multiple Sclerosis Drugs Market Dynamics – Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis
14.2.1. Novartis AG Switzerland
14.2.2. Teva Pharmaceutical industries Ltd. Israel
14.2.3. Biogen, Inc. U.S.
14.2.4. Merck & Co., Inc. U.S.
14.2.5. Sanofi S.A. France
14.2.6. Acorda Therapeuitics U.S.
14.2.7. Pfizer Inc. U.S.
14.2.8. Bayer AG Germany
14.2.9. Medtronic plc Questcor Pharmaceuiticals U.S.
15. Research Methodology
16. Key Assumptions and Acronyms


Please fill the following form to know more details about this Report




RELATED PRODUCTS



CHOOSE A FORMAT


  •  Single User Price : $ 4400
  •  Enterprise User License : $ 6600
  •  Corporate User License : $ 8900

Have A Question ?


  DOWNLOAD SAMPLE



TESTIMONIALS

I am completely satisfied with the information given in the sample pages of the report and I am waiting for the affirmative response from my peers and colleagues to purchase it.hey answered to all my queries promptly. I am highly satisfied!!
John Keats
We received a very quick response to all our queries on the RTLS report and we were also given a free consult with analyst for 15 minutes. It is refreshing (and increasingly rare) to have a new company go the extra mile to win the confidence of the customer
Ernest Hemingway
I would like to express my gratitude for the excellent service received this morning from the support team. They acknowledged my concern of adding me to the secondary user's list immediately. Thank you for this excellent, speedy and thoughtful service
Jacob Watson

CUSTOM RESEARCH

Still haven't found what you're looking for ?
Speak to our Custom Research Team